Mutational Signature Analysis Reveals Widespread Contribution of Pyrrolizidine Alkaloid Exposure to Human Liver Cancer. Issue 1 (15th June 2021)

• Record Type: Journal Article
• Authors: He, Yisheng; Shi, Mai; Wu, Xu; Ma, Jiang; Ng, Kevin Tak‐Pan; Xia, Qingsu; Zhu, Lin; Fu, Peter Pi‐Cheng; Man, Kwan; Tsui, Stephen Kwok‐Wing; Lin, Ge
• Is Part Of: Hepatology. Volume 74:Issue 1(2021)
• Page Start: 264
• Page End: 280
• Publication Date: 2021-06-15
• Subjects: Heart -- Diseases -- Nursing -- Periodicals; Lungs -- Diseases -- Nursing -- Periodicals; Intensive care nursing -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1002/hep.31723
• Languages: English
• ISSNs: 0270-9139

Abstract

Abstract : Background and Aims: Mutational signature analyses are an effective tool in identifying cancer etiology. Humans are frequently exposed to pyrrolizidine alkaloids (PAs), the most common carcinogenic phytotoxins widely distributed in herbal remedies and foods. However, due to the lack of human epidemiological data, PAs are classified as group II hepatocarcinogens by the World Health Organization. This study identified a PA mutational signature as the biomarker to investigate the association of PA exposure with human liver cancer. Approach and Results: Pyrrole‐protein adducts (PPAs), the PA exposure biomarker, were measured and found in 32% of surgically resected specimens from 34 patients with liver cancer in Hong Kong. Next, we delineated the mode of mutagenic and tumorigenic actions of retrorsine, a representative PA, in mice and human hepatocytes (HepaRG). Retrorsine induced DNA adduction, DNA damage, and activation of tumorigenic hepatic progenitor cells, which initiated hepatocarcinogenesis. PA mutational signature, as the unique molecular fingerprint of PA‐induced mutation, was derived from exome mutations in retrorsine‐exposed mice and HepaRG cells. Notably, PA mutational signature was validated in genomes of patients with PPA‐positive liver cancer but not patients with PPA‐negative liver cancer, confirming the specificity of this biomarker in revealing PA‐associated liver cancers. Furthermore, we examined the established PA mutational signature in 1, 513 liver cancer genomes and found that PA‐associated liver cancers were potentially prevalent in Asia (Mainland China [48%], Hong Kong [44%], Japan [22%], South Korea [6%], Southeast Asia [25%]) but minor in Western countries (North America [3%] and Europe [5%]). Conclusions: This study provides a clinical indication of PA‐associated liver cancer. We discovered an unexpectedly extensive implication of PA exposure in patients with liver cancer, laying the scientific basis for precautionary approaches and prevention of PA‐associated human liver cancers.